Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables - Accured (2019 - 2025)

Spyre Therapeutics' Receivables - Accured history spans 7 years, with the latest figure at $3.6 million for Q3 2025.

  • For Q3 2025, Receivables - Accured rose 111.76% year-over-year to $3.6 million; the TTM value through Sep 2025 reached $3.6 million, up 111.76%, while the annual FY2024 figure was $3.4 million, 277.78% up from the prior year.
  • Receivables - Accured reached $3.6 million in Q3 2025 per SYRE's latest filing, up from $3.5 million in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $3.6 million in Q3 2025 to a low of $100000.0 in Q3 2021.
  • Average Receivables - Accured over 5 years is $1.3 million, with a median of $650000.0 recorded in 2023.
  • Peak YoY movement for Receivables - Accured: tumbled 50.0% in 2021, then skyrocketed 1700.0% in 2024.
  • A 5-year view of Receivables - Accured shows it stood at $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then skyrocketed by 800.0% to $900000.0 in 2023, then surged by 277.78% to $3.4 million in 2024, then grew by 5.88% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Receivables - Accured are $3.6 million (Q3 2025), $3.5 million (Q2 2025), and $3.4 million (Q1 2025).